• Je něco špatně v tomto záznamu ?

Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention

J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, P. Tomašov, D. Tesař

. 2011 ; 107 (9) : 1295-1299. [pub] 20110223

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027037

Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p=0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p<0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027037
003      
CZ-PrNML
005      
20160502070511.0
007      
ta
008      
120816s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.amjcard.2010.12.040 $2 doi
035    __
$a (PubMed)21349484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Veselka, Josef, $d 1965- $7 pna2005261820 $u Department of Cardiology, Cardiovascular Center, University Hospital Motol, 2nd Medical School, Charles University, Prague, Czech Republic. veselka.josef@seznam.cz
245    10
$a Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention / $c J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, P. Tomašov, D. Tesař
520    9_
$a Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p=0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p<0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a angina pectoris $x farmakoterapie $x terapie $7 D000787
650    _2
$a balónková koronární angioplastika $7 D015906
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyseliny heptylové $x aplikace a dávkování $7 D006538
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $7 D019161
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrroly $x aplikace a dávkování $7 D011758
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zemánek, David, $d 1972- $7 xx0079099 $u Department of Cardiology, University Hospital Motol, Prague, Czech Republic. zejada@seznam.cz
700    1_
$a Hájek, Petr $7 xx0071248 $u Department of Cardiology, Charles University and University Hospital Motol, V Uvalu 84, Prague 5 150 06, Czech Republic. petr.hajek@fnmotol.cz
700    1_
$a Malý, Martin, $d 1966- $7 mzk2004241073 $u Department of Cardiology, University Hospital Motol, 1st Medical Faculty, Prague, Czech Republic. martin.maly@fnmotol.cz
700    1_
$a Adlová, Radka $7 xx0139523
700    1#
$a Martinkovičová, Lucia. $7 _AN033108 $u Department of Cardiology, 2nd Medical School of Charles University and University Hospital Motol, Prague, Czech Republic
700    1#
$a Tomašov, Pavol, $d 1982- $7 xx0243010 $u Cardiology Department, Cardiovascular Center, University Hospital Motol, Prague, Czech Republic
700    1_
$a Tesař, David $7 xx0081874 $u Department of Antibody Engineering, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
773    0_
$w MED00000236 $t The American journal of cardiology $x 1879-1913 $g Roč. 107, č. 9 (2011), s. 1295-1299
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21349484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160502070614 $b ABA008
999    __
$a ok $b bmc $g 949079 $s 784383
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 107 $c 9 $d 1295-1299 $e 20110223 $i 1879-1913 $m The American journal of cardiology $n Am J Cardiol $x MED00000236
LZP    __
$b NLK122 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Možnosti archivace